Evrópusambandið - hollenska - EMA (European Medicines Agency)

the medicines company uk ltd - bivalirudin - acute kransslagader syndroom - antitrombotische middelen - angiox is geïndiceerd als een anticoagulans bij volwassen patiënten die een percutane coronaire interventie (pci) ondergaan, waaronder patiënten met st-segment-elevatie-myocardiaal infarct (stemi) die primaire pci ondergaan. angiox is ook geïndiceerd voor de behandeling van volwassen patiënten met instabiele angina pectoris en non-st-segment-elevatie myocard infarct (ua / nstemi) gepland voor dringende of vroege interventie. angiox moet worden toegediend met aspirine en clopidogrel.

Evrópusambandið - hollenska - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - antitrombotische middelen - xarelto, co-toegediend met acetylsalicylzuur (asa), alleen of met asa plus clopidogrel of ticlopidine, is geïndiceerd voor de preventie van atherothrombotic gebeurtenissen bij volwassen patiënten na een acuut coronair syndroom (acs) met verhoogde cardiale biomarkers. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. preventie van veneuze trombo-embolie (vte) bij volwassen patiënten die een electieve heup- of knievervangende operatie ondergaan. behandeling van diepe veneuze trombose (dvt) en longembolie (pe) en preventie van recidiverende dvt en pe bij volwassenen. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Evrópusambandið - hollenska - EMA (European Medicines Agency)

merck sharp dohme limited - vorapaxar sulfaat - myocardinfarct - antitrombotische middelen - zontivityis geïndiceerd voor de vermindering van atherothrombotic gebeurtenissen in volwassen patiënten met een geschiedenis van myocardiaal infarct (mi)co-toegediend met acetylsalicylzuur (asa) en, in voorkomend geval, clopidogrel; of - symptomatisch perifeer arterieel vaatlijden(pad), co-toegediend met acetylsalicylzuur (asa) of, in voorkomend geval, clopidogrel.

Evrópusambandið - hollenska - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotische middelen - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Evrópusambandið - hollenska - EMA (European Medicines Agency)

substipharm - prasugrel - acute coronary syndrome; angina, unstable; myocardial infarction - antitrombotische middelen - efient, gecombineerd toegediend met acetylsalicylzuur (asa), is geïndiceerd voor de preventie van atherotrombotische bijwerkingen bij patiënten met acuut coronair syndroom (i. unstable angina pectoris, niet-st-segment-elevatie myocardinfarct [ua / nstemi] of st-segment-elevatie myocardinfarct [stemi]) in primaire of vertraagde percutane coronaire interventie (pci).

Evrópusambandið - hollenska - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - cangrelor - acute coronary syndrome; vascular surgical procedures - antitrombotische middelen - kengrexal, samen met acetylsalicylzuur (asa), beheerd is geïndiceerd voor de vermindering van trombotische cardiovasculaire gebeurtenissen bij volwassen patiënten met coronaire hartziekte ondergaan percutane coronaire interventie (pci) die niet hebben ontvangen van een mondelinge p2y12-remmer voorafgaand aan de pci-procedure en in wie orale therapie met p2y12-remmers is niet haalbaar of wenselijk.

Evrópusambandið - hollenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotische middelen - preventie van veneuze trombo-embolie (vte) bij volwassen patiënten die een electieve heup- of knievervangende operatie ondergaan. behandeling van diepe veneuze trombose (dvt) en longembolie (pe) en preventie van recidiverende dvt en pe bij volwassenen. (see section 4. 4 for haemodynamically unstable pe patients. behandeling van diepe veneuze trombose (dvt) en longembolie (pe) en preventie van recidiverende dvt en pe bij volwassenen. (see section 4. 4 voor haemodynamically instabiel pe-patiënten). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandeling van diepe veneuze trombose (dvt) en longembolie (pe) en preventie van recidiverende dvt en pe bij volwassenen. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 en 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandeling van diepe veneuze trombose (dvt) en longembolie (pe) en preventie van recidiverende dvt en pe bij volwassenen. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Belgía - hollenska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - rivaroxaban 10 mg - filmomhulde tablet - rivaroxaban

Belgía - hollenska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - rivaroxaban 15 mg (rode tablet (15 mg)); rivaroxaban 20 mg (bruinrode tablet (20 mg)) - filmomhulde tablet - rivaroxaban

Belgía - hollenska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - rivaroxaban 15 mg - filmomhulde tablet - rivaroxaban